ReVas Inc.
This article was originally published in Start Up
Executive Summary
ReVas Inc. believes that vasectomy would be a more desirable form of permanent birth control if men knew that the procedure could be easily reversed. The company aims to develop such a method, inserting a nylon stent into the vas deferens to prevent sperm passage, with a portion left outside the vas for venting and to facilitate removal.
You may also be interested in...
Permanent Contraception
Given the huge impact that having a baby has on every aspect of a woman's life--and that of her mate--it's small wonder that a growing number of companies are aiming to offer Baby Boomers improved contraceptive choices. Some are developing devices to make the widely performed tubal ligation surgery, which renders women sterile, less invasive, more convenient and safer than it has been to date. At least one firm hopes to give men a chance to participate in family planning via reversible vasectomization.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.